Prostate-specific membrane antigen (PSMA)-targeted PET imaging of prostate cancer: an update on important pitfalls
The continuing adoption of prostate specific membrane antigen (PSMA)-targeted PET for
prostate cancer molecular imaging requires imagers and clinicians alike to be aware of the …
prostate cancer molecular imaging requires imagers and clinicians alike to be aware of the …
Prostate-Specific Membrane Antigen–Targeted Therapies for Prostate Cancer: Towards Improving Therapeutic Outcomes
Context Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein
overexpressed in most prostate cancers and exploited as a target for PSMA-targeted …
overexpressed in most prostate cancers and exploited as a target for PSMA-targeted …
Influence of androgen deprivation therapy on PSMA expression and PSMA-ligand PET imaging of prostate cancer patients
S Vaz, B Hadaschik, M Gabriel, K Herrmann… - European Journal of …, 2020 - Springer
Prostate cancer (PCa) is the second most common solid tumour in men with more than 1.3
million cases diagnosed and more than 350,000 deaths estimated to have occurred in 2018 …
million cases diagnosed and more than 350,000 deaths estimated to have occurred in 2018 …
Prospective study on the effect of short-term androgen deprivation therapy on PSMA uptake evaluated with 68Ga-PSMA-11 PET/MRI in men with treatment-naïve …
O Ettala, S Malaspina, T Tuokkola, P Luoto… - European Journal of …, 2020 - Springer
Purpose Based on in vitro studies, it is known that androgen deprivation therapy (ADT)
increases prostate-specific membrane antigen (PSMA) expression. Therefore, we …
increases prostate-specific membrane antigen (PSMA) expression. Therefore, we …
Molecular imaging of bone metastases and their response to therapy
Bone metastases are common, especially in more prevalent malignancies such as breast
and prostate cancer. They cause significant morbidity and draw on health-care resources …
and prostate cancer. They cause significant morbidity and draw on health-care resources …
Impact of three-month androgen deprivation therapy on [68Ga] Ga-PSMA-11 PET/CT indices in men with advanced prostate cancer—results from a pilot prospective …
Simple Summary Positron emission tomography/computed tomography (PET/CT) with
prostate-specific membrane antigen (PSMA)-specific tracers is gaining traction for prostate …
prostate-specific membrane antigen (PSMA)-specific tracers is gaining traction for prostate …
Monitoring PSMA Responses to ADT in Prostate Cancer Patient-Derived Xenograft Mouse Models Using [18F]DCFPyL PET Imaging
J Roy, ME White, F Basuli, ACL Opina, K Wong… - Molecular imaging and …, 2021 - Springer
Purpose PSMA overexpression has been associated with aggressive prostate cancer (PCa).
However, PSMA PET imaging has revealed highly variable changes in PSMA expression in …
However, PSMA PET imaging has revealed highly variable changes in PSMA expression in …
[68Ga]Ga-PSMA-11 PET before and after initial long-term androgen deprivation in patients with newly diagnosed prostate cancer: a retrospective single-center study
S Hoberück, S Löck, R Winzer, K Zöphel, M Froehner… - EJNMMI research, 2020 - Springer
Purpose The study aimed to evaluate the effect of androgen deprivation therapy (ADT) on
PSMA imaging and its correlation to the PSA concentration by comparing qualitative and …
PSMA imaging and its correlation to the PSA concentration by comparing qualitative and …
Nuclear medicine imaging for bone metastases assessment: what else besides bone scintigraphy in the era of personalized medicine?
E Ouvrard, A Kaseb, N Poterszman, C Porot… - Frontiers in …, 2024 - frontiersin.org
Accurate detection and reliable assessment of therapeutic responses in bone metastases
are imperative for guiding treatment decisions, preserving quality of life, and ultimately …
are imperative for guiding treatment decisions, preserving quality of life, and ultimately …
Bone and lymph node flare to androgen deprivation therapy in metastatic hormone-sensitive prostate cancer on 18F–prostate-specific membrane antigen PET/CT with …
Y Lu - Clinical nuclear medicine, 2022 - journals.lww.com
A 72-year-old man with prostate cancer was found to have prostate-specific membrane
antigen (PSMA)–avid oligometastasis on initial staging with 18 F-DCFPyL PET/CT …
antigen (PSMA)–avid oligometastasis on initial staging with 18 F-DCFPyL PET/CT …